Connect with us

Markets

Mind-Bending Medicine: An Overview of Psychedelic Substances

Published

on

psychedelic medicine research infographic

An Overview of Psychedelic Substances

Fueled by a slew of new research, psychedelics may hold the key to treating a multitude of debilitating disorders such as addiction, PTSD, and depression.

But as an industry that has laid dormant for decades, it will need to shed its negative connotations that have limited its potential and undermined new discoveries for so long.

The infographic above showcases data from The Report on Psychedelics which explains seven of the most common psychedelic substances and examines the many mind-bending ways they could radically transform mental health as we know it.

Resurrecting a Stigmatized Industry

Although evidence of humans using psychedelics as medicine dates back thousands of years, it was not until the 1940s that psychiatrists became advocates of their therapeutic potential.

Unfortunately, recreational psychedelics became a symbol of the 1960’s counterculture movement, which contaminated the industry’s reputation. The U.S. responded by introducing the Controlled Substances Analogue Enforcement Act, deeming these drugs illegal and stymying research studies in the process.

Following some new discoveries in the early ‘90s however, psychedelics moved from the hands of festival-goers back to the labs of scientists. Since then, certain substances such as psilocybin have been granted breakthrough therapy status for treating depression by the U.S. FDA.

With these recent developments, new companies and investment opportunities are beginning to emerge in the psychedelics space. But these complex drugs are not always easy to understand—so let’s dive in.

What are Psychedelics?

Psychedelics are psychoactive substances that can alter perception, mood, and cognitive processes. There are two broad classifications of psychedelics that relate to chemical structure.

  • Entheogenic Plants: Plants or fungi that produce chemical substances that can cause hallucinations
  • Synthetic Drugs: Drugs created in laboratory setting to mimic the effects of entheogenic plants

Here are seven of the most common psychedelic substances explained:

DrugCharacteristicsLegal StatusConditions StudiedNumber of Studies/trials
Ayahuasca (Entheogenic plant)Traditional tea used in religious or spiritual rituals, mainly in South America.Not formally prohibited.Major depression1
DMT (Entheogenic plant)Powerful hallucinogen produced by multiple plants, humans, and animals with an unusually short bioavailability period.U.S.: Schedule I
Canada: Schedule III
UN: Schedule I
UK: Class A
Healthy subjects1
Ibogaine (Entheogenic plant)Derived from the tabernanthe iboga plant, a shrub found in the rainforest of western Africa.U.S.: Schedule I
Canada: Controlled
UN: Uncontrolled
UK: Illegal
Drug dependence, alcoholism2
Psilocybin (Entheogenic plant)Naturally occurring psychedelic chemical found in more than 100 species of mushrooms.U.S: Schedule 1
Canada: Schedule III
UN: Schedule I
UK: Class A
Depression, OCD, anorexia, migraines, cluster headaches, substance abuse40
Ketamine (Synthetic)Commonly used as an anesthetic and administered intravenously (IV) or intramuscularly (IM).U.S.: Schedule III
Canada: Schedule I
UN: Uncontrolled
UK: Class B
Depression, mental health disorders, suicidal ideations, pain and related conditions, healthy subjects925
LSD (Synthetic)First derived from ergot, a fungus that develops on grains such as rye.U.S: Schedule I
Canada: Schedule III
UN: Schedule I
UK: Class A
Cluster headaches, depression, anxiety, chronic pain, Healthy subjects
12
MDMA (Synthetic)Typically associated with rave culture, as it imparts feelings of joy combined with increased energy levels.U.S.: Schedule I
Canada: Schedule I
UN: Schedule I
UK: Class A
PTSD, autism, alcohol use disorder, Healthy subjects
43

To avoid history repeating itself, Johns Hopkins University has created the Center for Psychedelic and Consciousness Research with the aim of enforcing strict standards of scientific rigor for the industry to follow.

On the Precipice of Change

With sound scientific evidence and standards coming into place, it’s no surprise that investors—from bestselling author Tim Ferris to several established cannabis companies—are supporting the born-again industry.

Given the industry’s foothold in recreational use, a therapeutic comeback may be a tough pill for many to swallow. However, it is possible that we are on the precipice of not only a psychedelic revolution but more importantly, a mental health one.

“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy.”

—Stanislav Grof

Click for Comments

Markets

The European Stock Market: Attractive Valuations Offer Opportunities

On average, the European stock market has valuations that are nearly 50% lower than U.S. valuations. But how can you access the market?

Published

on

Bar chart showing that European stock market indices tend to have lower or comparable valuations to other regions.

Published

on

The following content is sponsored by STOXX

European Stock Market: Attractive Valuations Offer Opportunities

Europe is known for some established brands, from L’Oréal to Louis Vuitton. However, the European stock market offers additional opportunities that may be lesser known.

The above infographic, sponsored by STOXX, outlines why investors may want to consider European stocks.

Attractive Valuations

Compared to most North American and Asian markets, European stocks offer lower or comparable valuations.

IndexPrice-to-Earnings RatioPrice-to-Book Ratio
EURO STOXX 5014.92.2
STOXX Europe 60014.42
U.S.25.94.7
Canada16.11.8
Japan15.41.6
Asia Pacific ex. China17.11.8

Data as of February 29, 2024. See graphic for full index names. Ratios based on trailing 12 month financials. The price to earnings ratio excludes companies with negative earnings.

On average, European valuations are nearly 50% lower than U.S. valuations, potentially offering an affordable entry point for investors.

Research also shows that lower price ratios have historically led to higher long-term returns.

Market Movements Not Closely Connected

Over the last decade, the European stock market had low-to-moderate correlation with North American and Asian equities.

The below chart shows correlations from February 2014 to February 2024. A value closer to zero indicates low correlation, while a value of one would indicate that two regions are moving in perfect unison.

EURO
STOXX 50
STOXX
EUROPE 600
U.S.CanadaJapanAsia Pacific
ex. China
EURO STOXX 501.000.970.550.670.240.43
STOXX EUROPE 6001.000.560.710.280.48
U.S.1.000.730.120.25
Canada1.000.220.40
Japan1.000.88
Asia Pacific ex. China1.00

Data is based on daily USD returns.

European equities had relatively independent market movements from North American and Asian markets. One contributing factor could be the differing sector weights in each market. For instance, technology makes up a quarter of the U.S. market, but health care and industrials dominate the broader European market.

Ultimately, European equities can enhance portfolio diversification and have the potential to mitigate risk for investors

Tracking the Market

For investors interested in European equities, STOXX offers a variety of flagship indices:

IndexDescriptionMarket Cap 
STOXX Europe 600Pan-regional, broad market€10.5T
STOXX Developed EuropePan-regional, broad-market€9.9T
STOXX Europe 600 ESG-XPan-regional, broad market, sustainability focus€9.7T
STOXX Europe 50Pan-regional, blue-chip€5.1T
EURO STOXX 50Eurozone, blue-chip€3.5T

Data is as of February 29, 2024. Market cap is free float, which represents the shares that are readily available for public trading on stock exchanges.

The EURO STOXX 50 tracks the Eurozone’s biggest and most traded companies. It also underlies one of the world’s largest ranges of ETFs and mutual funds. As of November 2023, there were €27.3 billion in ETFs and €23.5B in mutual fund assets under management tracking the index.

“For the past 25 years, the EURO STOXX 50 has served as an accurate, reliable and tradable representation of the Eurozone equity market.”

— Axel Lomholt, General Manager at STOXX

Partnering with STOXX to Track the European Stock Market

Are you interested in European equities? STOXX can be a valuable partner:

  • Comprehensive, liquid and investable ecosystem
  • European heritage, global reach
  • Highly sophisticated customization capabilities
  • Open architecture approach to using data
  • Close partnerships with clients
  • Part of ISS STOXX and Deutsche Börse Group

With a full suite of indices, STOXX can help you benchmark against the European stock market.

Visual Capitalist Logo

Learn how STOXX’s European indices offer liquid and effective market access.

Click for Comments

You may also like

Visualizing Asia's Water Dilemma

Subscribe

Continue Reading
Voronoi, the app by Visual Capitalist. Where data tells the story. Download on App Store or Google Play

Subscribe

Popular